Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Anbio BiotechnologyNNNN -1.41%24 Cash Ratio is 135.24 as of Dec. 2025, which is 1889% above its 10-year median of 6.80. GuruFocus rates NNNN with a GF Score™ of 24/100. The stock has 2 warning signs investors should review. Among 812 Medical Devices & Instruments companies, Anbio Biotechnology ranks better than 99.75% on this metric.
Anbio Biotechnology has a Cash Ratio of 135.24. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Anbio Biotechnology's Cash Ratio or its related term are showing as below:
NNNN'
s Cash Ratio Range Over the Past 10 Years
Min: 1.76 Med: 6.8 Max: 135.24
Current: 135.24
During the past 5 years, Anbio Biotechnology's highest Cash Ratio was 135.24. The lowest was 1.76. And the median was 6.80.
NNNN's Cash Ratio is ranked better than 99.75% of 812
companies
in the Medical Devices & Instruments industry
Industry Median: 0.95
vs NNNN: 135.24
Anbio Biotechnology (NAS:NNNN) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Anbio Biotechnology Cash Ratio Related Terms
Anbio Biotechnology Cash Ratio Historical Data
* Premium members only.
The historical data trend for Anbio Biotechnology's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Anbio Biotechnology's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anbio Biotechnology Cash Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Anbio Biotechnology's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Anbio Biotechnology's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anbio Biotechnology (NNNN) has a Cash Ratio of 135.24 as of Dec. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Anbio Biotechnology and its competitors. This is 1889% above median its historical median of 6.80. Over the past decade, Anbio Biotechnology's Cash Ratio has ranged from 1.76 to 135.24. According to the industry distribution chart, Anbio Biotechnology ranks #2 out of 812 companies in the Medical Devices & Instruments industry, placing it in the top 0.2%.
Is Anbio Biotechnology's Cash Ratio too high?
Anbio Biotechnology's current Cash Ratio of 135.24 is 1889% above median its 10-year median of 6.80. Over the past 10 years, this metric has ranged from a low of 1.76 to a high of 135.24. The Medical Devices & Instruments industry median Cash Ratio is 0.95. Anbio Biotechnology's value of 135.24 is 14135.8% above this industry median. Based on the distribution chart, Anbio Biotechnology ranks #2 out of 812 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Anbio Biotechnology has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Anbio Biotechnology's Cash Ratio compare to ANGO and OSUR?
According to the Medical Devices & Instruments industry distribution chart, Anbio Biotechnology ranks #2 out of 812 companies for Cash Ratio. This places Anbio Biotechnology in the top 0% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 0.95. Anbio Biotechnology's value of 135.24 is 14135.8% above this benchmark. Historically, Anbio Biotechnology's own Cash Ratio has ranged from 1.76 to 135.24 over the past decade. While the company's 10-year median is 6.80 vs. the industry median of 0.95, Anbio Biotechnology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Devices & Instruments company?
The median Cash Ratio among Medical Devices & Instruments companies is 0.95, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anbio Biotechnology's current Cash Ratio of 135.24 is 14135.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Anbio Biotechnology and its competitors. For the Medical Devices & Instruments industry, the median Cash Ratio is 0.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anbio Biotechnology's current Cash Ratio is 135.24, which is 1889% above median its own 10-year median of 6.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anbio Biotechnology stock overvalued right now?
Anbio Biotechnology (NNNN) has a current Cash Ratio of 135.24. The current Cash Ratio is 135.24, which is 1889% above median its 10-year median of 6.80 and 14135.8% above the Medical Devices & Instruments industry median of 0.95. Anbio Biotechnology's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Anbio Biotechnology (NNNN), the current Cash Ratio is 135.24 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).
24GF Score
Get the complete analysis for NNNN
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NNNN has been successfully added to your 
